NCT04745312 is a NA clinical trial of Visible light in Non-visual Effects of Light, sponsored by Brigham and Women's Hospital.

Who is sponsoring NCT04745312?

NCT04745312 is sponsored by Brigham and Women's Hospital.

What drugs are being tested in NCT04745312?

Interventions in NCT04745312: Visible light.

What condition does NCT04745312 study?

NCT04745312 studies Non-visual Effects of Light.

Is NCT04745312 still recruiting?

NCT04745312 is currently status unknown. Last updated 18 February 2022.

Last reviewed 2022-02-18 · How we verify

NCT04745312

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Lighting Supplementation on Daytime Cognition

Status unknown NA Last updated 18 February 2022

What this trial tests

NA trial testing Visible light in Non-visual Effects of Light in 16 participants. Status unknown.

Timeline

1 March 2021

Primary endpoint
1 March 2022

1 March 2022

Quick facts

Lead sponsor	Brigham and Women's Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	16
Start date	1 March 2021
Primary completion	1 March 2022
Estimated completion	1 March 2022
Sites	1 location across United States

Drugs / interventions tested

Visible light

Conditions studied

Non-visual Effects of Light — all drugs for Non-visual Effects of Light →

Sponsor

Brigham and Women's Hospital

Who can join

Adults 18 to 30, any sex, with Non-visual Effects of Light. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to examine the efficacy of supplementing sub-optimal ambient room lighting with a task lamp on working memory and procedural learning.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Supplementation of ambient lighting with a task lamp improves daytime alertness and cognitive performance in sleep-restricted individuals.
Grant LK, Crosthwaite PC, Mayer MD, Wang W, et al · · 2023 · cited 3× · PMID 37026184 · DOI 10.1093/sleep/zsad096

Verify or expand the search:

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04745312 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
Last refreshed: 18 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04745312.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing